The disclosure provides compounds having formula (I): ##STR00001##
and the pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2, R.sub.2, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.

To provide a method for producing a phosphoryl imide salt represented by the following general formula (1) at a satisfactory yield by cation exchange. The method comprises the step of performing cation exchange by bringing a phosphoryl imide salt represented by the following general formula (2) into contact with a cation exchange resin having M.sup.1 n+ or a metal salt represented by the general formula (4) in an organic solvent having a water content of 0.3% by mass or less.

##STR00001##

A flame-retardant sugar derivative, a process for forming a flame-retardant sugar derivative, and an article of manufacture comprising a flame-retardant sugar derivative are disclosed. The flame-retardant sugar derivative can be synthesized from sorbitol, gluconic acid, or glucaric acid obtained from a bio-based source, and can have at least one phosphoryl or phosphonyl moiety. The process for forming the flame-retardant sugar derivative can include reacting sorbitol, gluconic acid, or glucaric acid and a flame-retardant phosphorus-based molecule to form the flame-retardant sugar derivative.

Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, L, L.sup.1, L.sup.2, L.sup.3, M and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.

The present invention is directed to new 5-ALA derivatives, particles and formulation thereof, related methods of preparation and methods of use thereof. In particular, the invention relates to compounds of the invention, particles and formulation thereof useful in the treatment of a cancer and/or the diagnosis of a cancer cell such as in photodynamic therapy or photodynamic diagnosis.

Provided are a divalent phosphazenium salt which is neutral and is excellent in thermal stability and aldehyde scavenging ability, and a method for producing the same. Also provided are a polyalkylene oxide composition having a volatile aldehyde amount reduced, having generation of odor and turbidity suppressed and being excellent in urethanization reactivity, and a method for producing such a polyalkylene oxide composition, as well as a polyurethane-forming composition containing the polyalkylene oxide composition. A divalent phosphazenium salt having a specific structure. Also, a polyalkylene oxide composition comprising a divalent phosphazenium salt having a specific structure and a polyalkylene oxide, a method for producing the same, and a polyurethane-forming composition containing the same.

Provided are a divalent phosphazenium salt which is neutral and is excellent in thermal stability and aldehyde scavenging ability, and a method for producing the same. Also provided are a polyalkylene oxide composition having a volatile aldehyde amount reduced, having generation of odor and turbidity suppressed and being excellent in urethanization reactivity, and a method for producing such a polyalkylene oxide composition, as well as a polyurethane-forming composition containing the polyalkylene oxide composition. A divalent phosphazenium salt having a specific structure. Also, a polyalkylene oxide composition comprising a divalent phosphazenium salt having a specific structure and a polyalkylene oxide, a method for producing the same, and a polyurethane-forming composition containing the same.

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

To provide a method for producing a phosphoryl imide salt represented by the following general formula (1) at a satisfactory yield by cation exchange. The method comprises the step of performing cation exchange by bringing a phosphoryl imide salt represented by the following general formula (2) into contact with a cation exchange resin having M.sup.1 n+ or a metal salt represented by the general formula (4) in an organic solvent having a water content of 0.3% by mass or less. ##STR00001##